Merck, a leading science and technology company, will present data at the ESMO 18 th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, ...
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, ...
The data included results from over 20,000 Medicare patients with metastatic colon or rectal cancer between the years 2000 and 2009. The study examined the percentage of these patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback